Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: We investigated the efficacy and tolerability of paliperidone extended-release (ER) tablets in patients with first-episode psychosis (n=75). Methods: This was an 8-week, open-label, multicenter trial. The primary outcome variable was scores on the Positive and Negative Syndrome Scale (PANSS); secondary measures included the Scale for the Assessment of Negative Symptoms (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of Functioning (GAF). To assess safety, we measured drug-related adverse events, weight, lipid-related variables, and prolactin and administered the Simpson–Angus Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU). Results: The administration of paliperidone ER resulted in significant improvement in the PANSS, SANS, CAI, and GAF scores (p＜0.001) over time. This improvement was evident as early as 1 week. The most frequent adverse events were akathisia, somnolence, anxiety, and sedation, which were well tolerated. Modest increases in weight and lipid profiles were also noted. Prolactin levels were substantially increased at the endpoint in both male and female patients. Conclusion: These results indicate that paliperidone ER is effective and is characterized by good tolerability in the treatment of positive and negative symptoms and cognitive functioning in first-episode psychosis.
Abstract
Objective: We investigated the efficacy and tolerability of paliperidone extended-release (ER) tablets in patients with first-episode psychosis (n=75). Methods: This was an 8-week, open-label, multicenter trial. The primary outcome variable was scores on the Positive and Negative Syndrome Scale (PANSS); secondary measures included the Scale for the Assessment of Negative Symptoms (SANS), the Cognitive Assessment Interview (CAI), and the Global Assessment of Functioning (GAF). To assess safety, we measured drug-related adverse events, weight, lipid-related variables, and prolactin and administered the Simpson–Angus Rating Scale (SARS), the Abnormal Involuntary Movement Scale (AIMS), the Barnes Akathisia Scale (BAS), the Arizona Sexual Experiences Scale (ASEX), and the Udvalg for Kliniske Undersogelser side effect rating scale (UKU). Results: The administration of paliperidone ER resulted in significant improvement in the PANSS, SANS, CAI, and GAF scores (p＜0.001) over time. This improvement was evident as early as 1 week. The most frequent adverse events were akathisia, somnolence, anxiety, and sedation, which were well tolerated. Modest increases in weight and lipid profiles were also noted. Prolactin levels were substantially increased at the endpoint in both male and female patients. Conclusion: These results indicate that paliperidone ER is effective and is characterized by good tolerability in the treatment of positive and negative symptoms and cognitive functioning in first-episode psychosis.
참고문헌 (50)
- Lieberman J, "Time course and biologic correlates of treatment response in first-episode schizophrenia", Arch Gen Psychiatry, 50, pp.369~376 (1993)
- Robinson DG, "Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder", Am J Psychiatry, 156, pp.544~549 (1999)
- McEvoy JP, "Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis:a randomized, double-blind 52-week comparison", Am J Psychiatry, 164, pp.1050~1060 (2007)
- Walter G, "The pharmacologic treatment of the early phase of first-episode psychosis in youths", Can J Psychiatry, 46, pp.803~809 (2001)
- Opjordsmoen S, "Stability of medication in early psychosis:a comparison between second-generation and low-dose first-generation antipsychotics", Early Interv Psychiatry, 3, pp.58~65 (2009)
- Kahn RS, "Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial", Lancet, 371, pp.1085~1097 (2008)
- Chatterjee A, "Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in nevermedicated schizophrenic patients", Am J Psychiatry, 152, pp.1724~1729 (1995)
- Jackie Curtis, "Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis", Early Intervention in Psychiatry, 10(3), pp.267~276 (2016), Wiley-Blackwell[DOI]
- Verma S, "Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis", Aust N Z J Psychiatry, 43, pp.812~817 (2009)
- Kampman O, "Indicators of medication compliance in first-episode psychosis", Psychiatry Res, 110, pp.39~48 (2002)
- Robinson DG, "Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder", Schizophr Res, 57, pp.209~219 (2002)
- Lautenschlager M, "Paliperidone-ER: first atypical antipsychotic with oral extended release formulation", Expert Rev Neurother, 8, pp.193~200 (2008)
- Conley R, "Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form", Curr Med Res Opin, 22, pp.1879~1892 (2006)
- Sheehan JJ, "Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents", Innov Clin Neurosci, 9, pp.17~23 (2012)
- Shah S, "Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia:A randomized, double-blind, multicentric trial", Ind Psychiatry J, 20, pp.25~31 (2011)
- Canuso CM, "Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and", or mood stabilizers, 2010, pp.30, 487~495
- Meltzer HY, "Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebocontrolled studies", J Clin Psychiatry, 69, pp.817~829 (2008)
- Si T, "An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis", Neuropsychiatr Dis Treat, 11, pp.87~95 (2015)
- First MB, "Structured clinical interview for DSM-IV Axis I Disorders SCID-I:clinician version, administration booklet" (1997), American Psychiatric Press
- Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Sanger TM, "Olanzapine versus haloperidol treatment in first-episode psychosis", Am J Psychiatry, 156, pp.79~87 (1999)
- Andreasen NC, "The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations", Br J Psychiatry Suppl, (7), pp.49~58 (1989)
- Keefe RS, "The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity", Am J Psychiatry, 163, pp.426~432 (2006)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-III-R" (1987), American Psychiatric Press
- Simpson GM, "A rating scale for extrapyramidal side effects", Acta Psychiatr Scand Suppl, 212, pp.11~19 (1970)
- Barnes TR, "A rating scale for drug-induced akathisia", Br J Psychiatry, 154, pp.672~676 (1989)
- Guy W, "ECDEU Assessment Manual for Psychopharmacology", US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, ~ (1976)
- McGahuey CA, "The Arizona Sexual Experience Scale (ASEX): reliability and validity", J Sex Marital Ther, 26, pp.25~40 (2000)
- Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand Suppl, 334, pp.1~100 (1987)
- Emsley R, "Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia:pooled data from three 52-week open-label studies", Int Clin Psychopharmacol, 23, pp.343~356 (2008)
- Gaebel W, "Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia", Eur Arch Psychiatry Clin Neurosci, 254, pp.129~140 (2004)
- Möller HJ, "Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia", Int J Neuropsychopharmacol, 11, pp.985~997 (2008)
- Schooler N, "Risperidone and haloperidol in first-episode psychosis:a long-term randomized trial", Am J Psychiatry, 162, pp.947~953 (2005)
- Lieberman JA, "Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol", Am J Psychiatry, 160, pp.1396~1404 (2003)
- Davidson M, "Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study", Schizophr Res, 93, pp.117~130 (2007)
- Kane JM, "A multicenter, randomized, doubleblind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy", J Clin Psychiatry, 70, pp.1348~1357 (2009)
- Agid O, "Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected", Arch Gen Psychiatry, 60, pp.1228~1235 (2003)
- Emsley RA, "Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study", Schizophr Bull, 25, pp.721~729 (1999), Risperidone Working Group
- Kopala LC, "Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone", Biol Psychiatry, 39, pp.296~298 (1996)
- Merlo MC, "Risperidone, 2 mg", day vs. 4 mg, J Clin Psychiatry, pp.2002, 63[DOI]
- Yap HL, "Risperidone in the treatment of first episode psychosis", Singapore Med J, 42, pp.170~173 (2001)
- Zalsman G, "Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study", J Child Adolesc Psychopharmacol, 13, pp.319~327 (2003)
- Kramer M, "Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia:a randomized, double-blind, placebo-controlled study", J Clin Psychopharmacol, 27, pp.6~14 (2007)
- Peuskens J, "Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice", Ann Gen Psychiatry, 13, pp.10~ (2014)
- Schmauss M, "Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study", Curr Med Res Opin, 28, pp.1395~1404 (2012)
- Marder SR, "Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study", Biol Psychiatry, 62, pp.1363~1370 (2007)
- Kim SW, "Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, openlabel, controlled trial", Int Clin Psychopharmacol, 27, pp.267~274 (2012)
- Kim SW, "The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 38, pp.228~235 (2012)
- de Leon J, "The pharmacokinetics of paliperidone versus risperidone", Psychosomatics, 51, pp.80~88 (2010)
- Gahr M, "Paliperidone extended-release: does it have a place in antipsychotic therapy?", Drug Des Devel Ther, 5, pp.125~146 (2011)